Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Sponsored by:

Stock Report: BioSpecifics Technologies Corp. (BSTC) Report Updated: Nov 16, 2009  |  Print This Page

Get more stock ratings by Louis Navellier

BioSpecifics Technologies Corp. (BSTC)

Rating: Buy Volatility: Conservative
Total Grade: B Industry: Biotechnology
  Competitors: AVGN, BTIM, ONTY, CRIS
hide

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: B down downgrade
Last Week: A same no change
Two Weeks Ago: A up no change
hide

BioSpecifics Technologies Corp. © quotemedia

hide

Company Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase for multiple indications in the United States. The company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase known as XIAFLEX for clinical indications in dupuytren’s disease, peyronie’s disease, and frozen shoulder. The XIAFLEX is under phase IIb clinical trial for the treatment of peyronie’s disease. BioSpecifics Technologies also focuses on the development of collagenase for various other clinical indications, including lipomas and cellulite. The company was founded in 1957 and is headquartered in Lynbrook, New York.

hide

Recent News: BioSpecifics Technologies Corp.